Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SAB Biotherapeutics Inc (SABS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: SABS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -6.36% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.31M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 63019 | Beta 0.45 | 52 Weeks Range 1.45 - 5.01 | Updated Date 03/27/2025 |
52 Weeks Range 1.45 - 5.01 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-26 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3422.67% |
Management Effectiveness
Return on Assets (TTM) -78.8% | Return on Equity (TTM) -174.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -11759594 | Price to Sales(TTM) 9.46 |
Enterprise Value -11759594 | Price to Sales(TTM) 9.46 | ||
Enterprise Value to Revenue 1.21 | Enterprise Value to EBITDA -1.49 | Shares Outstanding 9229270 | Shares Floating 6734232 |
Shares Outstanding 9229270 | Shares Floating 6734232 | ||
Percent Insiders 19.15 | Percent Institutions 28.68 |
Analyst Ratings
Rating 4.8 | Target Price 12.4 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
SAB Biotherapeutics Inc
Company Overview
History and Background
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary DiversitAbu2122 platform to develop new immunotherapies. Founded to address unmet needs in human health, particularly infectious diseases, inflammation, and cancer, SAB is focused on creating targeted polyclonal antibody therapies.
Core Business Areas
- DiversitAbu2122 Platform: SAB's DiversitAbu2122 platform is a proprietary technology that utilizes transgenic cattle to produce fully human polyclonal antibodies. This platform allows for rapid and scalable production of targeted antibody therapies.
- Immunotherapy Development: SAB focuses on developing immunotherapies for various indications, including infectious diseases (e.g., COVID-19, influenza), autoimmune diseases, and cancer. They are actively involved in clinical trials to evaluate the safety and efficacy of their antibody therapies.
Leadership and Structure
SAB Biotherapeutics is led by a management team with experience in biopharmaceutical development and commercialization. The organizational structure includes research and development, clinical operations, manufacturing, and business development functions.
Top Products and Market Share
Key Offerings
- SAB-185 (COVID-19):: SAB-185 is a fully-human polyclonal antibody therapeutic designed to treat and prevent COVID-19. While specific market share data isn't publicly available, SAB aimed to compete with other antibody therapies from companies like Regeneron (REGN) and Eli Lilly (LLY). This product did not succeed at market.
- SAB Platform (Research/Partnerships):: SAB's DiversitAb platform itself is a key offering, as they partner with other companies to develop novel antibody therapeutics. Revenue is generated through licensing and collaboration agreements. Potential competitors in this space include companies offering antibody discovery services and platforms.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. The demand for novel immunotherapies is increasing due to the rising prevalence of infectious diseases, autoimmune disorders, and cancer.
Positioning
SAB Biotherapeutics is positioned as an innovative player in the immunotherapy space, leveraging its unique DiversitAbu2122 platform to generate fully human polyclonal antibodies. Its competitive advantage lies in the potential for rapid and scalable production of targeted antibody therapies.
Total Addressable Market (TAM)
The TAM for immunotherapy is substantial, estimated in the hundreds of billions of USD annually. SAB is positioned to capture a portion of this market by developing and commercializing novel antibody therapies, but is likely a small portion. Now privatized it's market share is unknown.
Upturn SWOT Analysis
Strengths
- Proprietary DiversitAbu2122 platform
- Fully human polyclonal antibody production
- Potential for rapid and scalable manufacturing
- Experienced management team
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- High R&D costs
- Relatively small market capitalization.
Opportunities
- Expanding applications of DiversitAbu2122 platform
- Strategic partnerships and collaborations
- Positive clinical trial results
- Government funding and support
Threats
- Regulatory hurdles and delays
- Competition from larger biopharmaceutical companies
- Patent disputes
- Unsuccessful clinical trials
Competitors and Market Share
Key Competitors
- REGN
- LLY
- GSK
- AZN
Competitive Landscape
SAB Biotherapeutics faces strong competition from established pharmaceutical companies with greater resources and broader pipelines. SAB's competitive advantage lies in its DiversitAbu2122 platform. Due to market failure, its relative standing is not significant.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth was tied to progress in clinical trials and platform development. Growth was minimal.
Future Projections: Future growth depends on the successful development and commercialization of its immunotherapy candidates, but information is limited. SAB Biotherapeutics is now a private company.
Recent Initiatives: Recent initiatives likely focus on advancing its pipeline and securing partnerships following it's exit as a publicly traded company.
Summary
SAB Biotherapeutics, leveraging its unique DiversitAb platform, aimed to develop novel immunotherapies. However, it struggled to gain traction in a competitive market dominated by larger, well-established pharmaceutical companies, which is evidenced by the company going private. SAB's success hinges on securing partnerships and achieving clinical trial successes. Investors should note the inherent risks associated with early-stage biopharmaceutical companies.
Similar Companies
- REGN
- LLY
- GSK
- AZN
Sources and Disclaimers
Data Sources:
- SEC Filings (historical)
- Company Website (historical)
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is based on publicly available data and analyst estimates. It is not financial advice and should not be used as the sole basis for investment decisions. Market share and financial data is limited due to the delisting of the stock.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SAB Biotherapeutics Inc
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-02-09 | CEO & Executive Chairman Mr. Samuel J. Reich | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | |
Full time employees 57 | |||
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.